Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01366092 · ClinicalTrials.gov registry record · Phase 2

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 2
Development phase
35
Enrollment target
3
Study locations

NCT01366092 is a Phase 2 study of Chronic Graft Versus Host Disease that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 35 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01366092, a Phase 2 study of Chronic Graft Versus Host Disease, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
35 participants
Enrollment target
3
Study locations

Study Summary

Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it. This process is known as graft-versus-host-disease. It is thought that IL-2 may help control chronic GVHD by stopping the donor's immune system from 'rejecting' your body. In this research study, we are looking to see how IL-2 can be used in combination with steroids to treat cGVHD.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • DRUG Interleukin-2

Study Locations (3)

Massachusetts

  • Dana-Farber Cancer Institute - Boston
  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2011-07
Est. Completion 2026-12
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01366092

The ClinicalTrials.gov registry entry for NCT01366092 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (70% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Interleukin-2 is the first listed.

NCT01366092 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01366092 about?

NCT01366092 is a clinical study titled "Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease". Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it. This process is known as graft-versus-host-disease. It is thought that IL-2 may help con...

What is the current status of trial NCT01366092?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2011-07. Estimated completion is 2026-12.

What conditions does trial NCT01366092 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT01366092?

The interventions under investigation include: Interleukin-2 (DRUG).

Who is sponsoring clinical trial NCT01366092?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01366092 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.